Clinical Trial

BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM

Name: BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM — clinical trial record (NCT07407010)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CM336-001

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study is a prospective, single-arm, multicenter trial designed to evaluate the hematologic response rate and safety of BCMA/CD3 bispecific antibody bridging therapy prior to CAR-T cell infusion in patients with relapsed/refractory multiple myeloma (RRMM).

Trial Details

NCT Number	NCT07407010
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Relapsed Refractory Multiple Myeloma (RRMM)
Enrollment	10 participants
Start Date	2026-06-01
Primary Completion	2027-05-31 (estimated)
Study Completion	2028-05-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-12